At this week’s 2022 H.C. Wainwright BioConnect Virtual Conference, NRx identified the plans to move forward with a vanguard trial of the BriLife investigational vaccine for COVID-19 as a heterologous booster for those already vaccinated with mRNA vaccines.
NRX
Jan. 14, 2022
CEO Update: BriLife Investigational Vaccine for COVID-19 as a Booster
Dec. 15, 2021
NRx Pharmaceuticals Added to the Nasdaq® Biotech Index
NRx Pharmaceuticals announced that Nasdaq has added the company to the Nasdaq Biotechnology Index (Nasdaq:NBI) effective December 20, 2021. The NBI is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies.